摘要
弥漫大B细胞淋巴瘤是成人非霍奇金淋巴瘤中最常见的一种病理类型,其病死率高,预后相关因素多样,而18F-FDG PET/CT是目前唯一用解剖形式进行功能代谢和受体显像的技术,具有高敏感性、高特异性及功能显像的优点。在弥漫大B细胞淋巴瘤患者治疗前以及按标准治疗方案完成治疗后进行PET/CT检查,不仅有助于临床准确分期,而且在评估DLBCL患者预后以及监测复发方面均有一定价值,但中期PET/CT检查的预后评估意义目前仍有争议性。因此,本文就基线、中期、治疗后18F-FDG PET/CT扫描对弥漫大B细胞淋巴瘤的预后评估价值研究进行了综述。
Diffuse large B cell lymphoma（DLBCL） is one of the most common pathological type ot non Hodgkin＇s lymphoma in adult, with a high mortality and a variety of prognostic factors. ^18F-FDG PET/CT, a functional imaging modality used for staging and monitoring response of a variety of human neoplasia to treatment, has a higher sensitivity and specificity than conventional anatomical imaging. Patinets taking ^18F-FDG PET/CT scanning for DLBCL before treatment and after complete standard treatment of DLBCL patients not only contributes to the clinical accurate staging, but also has a certain value in evaluating the prognosis of DLBCL patients and monitoring of recurrence. However, the value of interim PET/CT for evaluation of prognosis remains controversial. Therefore, this review focuses on the research progress of ^18 F-FDG PET/CT for evaluating prognosis of patient with DLBCL, including baseline, interim and post-treatment ^18F-FDG PET/CT.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2015年第1期255-260,共6页
Journal of Experimental Hematology
基金
中国人民解放军总医院临床科研扶持基金项目(2012FCTSYS-4002)
